Ikarian Capital, LLC Passage Bio, Inc. Transaction History

Ikarian Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.63 - $3.46 $117,125 - $248,621	-71,856 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$2.66 - $6.49 $10,658 - $26,005	4,007 Added 5.91%	71,856 $223,000
Q3 2021 Nov 15, 2021	SELL	$9.73 - $15.52 $759,027 - $1.21 Million	-78,009 Reduced 53.48%	67,849 $677,000
Q1 2021 May 17, 2021	BUY	$16.24 - $29.83 $148,774 - $273,272	9,161 Added 6.7%	145,858 $2.55 Million
Q4 2020 Feb 12, 2021	BUY	$14.28 - $29.73 $1.95 Million - $4.06 Million	136,697 New	136,697 $3.5 Million

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $35.4M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.